Pemetrexed plus carboplatin or oxaliplatin in advanced non-small cell lung cancer

Seminars in Oncology

Volumn 32, Issue SUPPL. 2, 2005, Pages

  Scagliotti, Giorgio V ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; FOLIC ACID ANTAGONIST; OXALIPLATIN; PEMETREXED;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL STRUCTURE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; FATIGUE; HUMAN; HYPERSENSITIVITY REACTION; LUNG NON SMALL CELL CANCER; METASTASIS; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; VOMITING;

EID: 16244378895     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.02.006     Document Type: Article

References (15)

1. J.H. Schiller, D. Harrington, C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
2. K. Kelly, J. Crowley, P.A. Bunn Jr Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer A Southwest Oncology Group trial J Clin Oncol 19 2001 3210 3218
3. G. Scagliotti, F. De Marinis, M. Rinaldi Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Oncol 20 2002 4285 4291
4. F. Fossella, J.R. Pereira, J. von Pawel Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer The TAX 326 study group J Clin Oncol 21 2003 3016 3024
5. C.J. Allegra Antifolates The next millennium Semin Oncol 26 suppl 6 1999 1 2
6. H. Calvert, P.A. Bunn Jr Future directions in the development of pemetrexed Semin Oncol 29 suppl 5 2002 54 61
7. E.C. Taylor, H.H. Patel Synthesis of pyrazolo(3,4,-d)pyrimidine analogues of the potent antitumor agent n-{4-(2-(2-amino-4(3h)-oxo-7h-pyrrolo(2,3- d)pyrimidin-5-yl)ethyl)benzoyl}-l-glutamic acid (LY231514) Tetrahedron Lett 48 1992 8089 8100
8. C. Shih, L.G. Mendelsohn, V.J. Chen Multiple folate enzyme inhibition Mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA) Adv Enzyme Regul 38 1998 135 152
9. J. Rusthoven, E. Eisenhauer, C. Butts Multitargeted antifolate, LY231514, as first-line chemotherapy for patients with advanced non-small-cell lung cancer A phase II study J Clin Oncol 17 1999 1194 1199
10. S.J. Clarke, R. Abratt, L. Goedhals Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer Ann Oncol 13 2002 737 741
11. C. Manegold, U. Gatzemeier, J. von Pawel Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin A multicenter phase II trial Ann Oncol 11 2000 435 440
12. F.A. Shepherd, J. Dancey, A. Arnold Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma A study of the National Cancer Institute of Canada Clinical Trials Group Cancer 92 2001 595 600
13. G.V. Scagliotti, C. Kortsik, G.G. Dark Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer A multicenter, randomized, phase II trial Clin Cancer Res 11 2005 690 696
14. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10
15. S.J. Pocock, R. Simon Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial Biometrics 31 1975 103 115